Godói Isabella P, Santos André S, Reis Edna A, Lemos Livia L P, Brandão Cristina M R, Alvares Juliana, Acurcio Francisco A, Godman Brian, Guerra Júnior Augusto A
Programa de Pós-graduação em Medicamentos e Assistência Farmacêutica, Faculdade de Farmácia, Universidade Federal de Minas GeraisBelo Horizonte, Brazil; SUS Collaborating Centre for Technology Assessment and Excellence in Health, Faculdade de Farmácia, Universidade Federal de Minas GeraisBelo Horizonte, Brazil.
Programa de Pós-graduação em Medicamentos e Assistência Farmacêutica, Faculdade de Farmácia, Universidade Federal de Minas Gerais Belo Horizonte, Brazil.
Front Pharmacol. 2017 Feb 2;8:41. doi: 10.3389/fphar.2017.00041. eCollection 2017.
Dengue virus is a serious global health problem with an estimated 3.97 billion people at risk for infection worldwide. In December 2015, the first vaccine (CYD-TDV) for dengue prevention was approved in Brazil, developed by Sanofi Pasteur. However, given that the vaccine will potentially be paid via the public health system, information is need regarding consumers' willingness to pay for the dengue vaccine in the country as well as discussions related to the possible inclusion of this vaccine into the public health system. This was the objective of this research. : We conducted a cross-sectional study with residents of Greater Belo Horizonte, Minas Gerais, about their willingness to pay for the CYD-TDV vaccine. : 507 individuals were interviewed. These were mostly female (62.4%) had completed high school (62.17%), were working (74.4%), had private health insurance (64.5%) and did not have dengue (67.4%). The maximum median value of consumers' willingness to pay for CYD-TDV vaccine is US$33.61 (120.00BRL) for the complete schedule and US$11.20 (40.00BRL) per dose. At the price determined by the Brazil's regulatory chamber of pharmaceutical products market for the commercialization of Dengvaxia for three doses, only 17% of the population expressed willingness to pay for this vaccine. : Brazil is currently one of the largest markets for dengue vaccine and the price established is a key issue. We believe the manufacturer should asses the possibility of lower prices to reach a larger audience among the Brazilian population.
登革热病毒是一个严重的全球健康问题，全球估计有39.7亿人面临感染风险。2015年12月，赛诺菲巴斯德公司研发的首款预防登革热的疫苗（CYD - TDV）在巴西获批。然而，鉴于该疫苗可能通过公共卫生系统支付费用，因此需要了解该国消费者为登革热疫苗支付费用的意愿，以及有关将该疫苗纳入公共卫生系统的可能性的讨论。这就是本研究的目的。我们对米纳斯吉拉斯州大贝洛奥里藏特市的居民进行了一项横断面研究，了解他们为CYD - TDV疫苗支付费用的意愿。共采访了507人。这些人大多为女性（62.4%），完成了高中学业（62.17%），有工作（74.4%），拥有私人医疗保险（64.5%），且未感染登革热（67.4%）。消费者为CYD - TDV疫苗完整接种方案支付费用的最高中位数为33.61美元（120.00巴西雷亚尔），每剂为11.20美元（40.00巴西雷亚尔）。按照巴西药品市场监管机构确定的登革热疫苗Dengvaxia三剂的商业化价格，只有17%的人口表示愿意为此疫苗付费。巴西目前是登革热疫苗最大的市场之一，确定的价格是一个关键问题。我们认为制造商应评估降低价格的可能性，以便在巴西民众中获得更多受众。
